Viewing
|Articles|December 4, 2007

Open letter from Genentech

Click here to read Genentech's open letter to ophthalmologists, outlining its reason for imposing restrictions on the use of Avastin.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe

Latest CME